TGTX
TG Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +5.9% ·
share flow -4.9% ·
net new positions 0.0%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 55.52K | $2.21M | n/a | −1 |
| Q2 2026 | 115 | +11 | 84.48M | $4.64B | +13 | −4 |
| Q1 2026 | 109 | 0 | 78.24M | $2.60B | +7 | −7 |
| Q4 2025 | 108 | 0 | 85.68M | $2.55B | n/a | n/a |
| Q3 2025 | 18 | +1 | 56.55M | $2.04B | +1 | −1 |
| Q2 2025 | 15 | 0 | 56.34M | $2.03B | +1 | −1 |
| Q1 2025 | 12 | +2 | 14.38M | $567.04M | +2 | n/a |
| Q4 2024 | 10 | -1 | 14.56M | $438.37M | n/a | −1 |
| Q3 2024 | 10 | -3 | 5.57M | $130.22M | n/a | −3 |
| Q2 2024 | 13 | n/a | 11.93M | $212.32M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 21.30M | -2.4% | $769.48M | 0.0% | ▼ Trim | 2 | SEC ↗ ×16 |
| 2 | The Vanguard Group ✦ (passive) | 15.52M | -1.8% | $560.71M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 8.10M | +6.3% | $292.63M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 3.44M | -1.3% | $125.04M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 5 | Goldman Sachs Group ✦ | 1.52M | n/a | $54.89M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 6 | Morgan Stanley ✦ | 1.25M | n/a | $45.08M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 7 | Citadel Advisors ✦ | 992.70K | -5.0% | $35.86M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 8 | T. Rowe Price ✦ | 958.47K | -38.1% | $34.62M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 9 | Two Sigma Investments ✦ | 889.87K | +45.0% | $32.15M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 711.34K | -54.2% | $25.70M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 11 | JPMorgan Chase ✦ | 455.87K | n/a | $16.47M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 12 | Point72 Asset Management ✦ | 365.83K | -49.0% | $13.22M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Bridgewater Associates ✦ | 342.15K | New | $12.36M | 0.0% | New | 1 | SEC ↗ |
| 14 | Millennium Management ✦ | 290.89K | -52.8% | $10.51M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 232.02K | +96.4% | $8.38M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 16 | AQR Capital Management ✦ | 67.81K | +103.3% | $2.45M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 17 | Wellington Management ✦ | 60.60K | -95.1% | $2.19M | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 18 | Gotham Asset Management ✦ | 45.33K | 0.0% | $1.64M | 0.0% | Held | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Bridgewater Associates | $12.36M | 0.0% |
Exited
| Norges Bank | $3.23M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 359 holders, 105.22M shares, $3.44B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 5.00K sh · $274,800
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology